Answers are grounded in this paper and cite their sources.
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. (Funded by AstraZeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.).
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: